| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Teladoc Health, Inc.$9.62
-0.11 (-1.08%)
F 17Pipeline Score Tools & Services · Commercial
Market Cap
909.82 M
EPS
-1.14
P/E Ratio
-4.47 $
Value Trade
35.38 M
SEC Financials
Q1 2026Dilution Risk
Revenue
613.85 M
R&D Expenses
67.86 M
Operating CF
9.52 M
Total Assets
2.81 B
Total Liabilities
1.47 B
Equity
1.34 B
D/E Ratio
12,345
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
750.74 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
Apr 30, 2026
Overview
Volume
1.04 M
52 Week Range
4.40 - 9.77
% held by Insiders
2.57 %
% held by Institutions
80.2 %
Enterprise Value
1.17 B
Total Shares
180.36 M
Short %
15.59 %
Float Shares
179.28 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
F17
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 15%
Micro Cap (rank 776 of 912)
Percentile RankTeladoc Health, Inc. has significant pipeline risk (17/100).
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in TDOC
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
TDOC Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-14 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-14 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-14 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-TDOC
Jul 15, 2026▼ -1.1%today
Teladoc Health to Announce Second Quarter 2026 Financial Results
Teladoc Health Inc. will announce its second quarter 2026 financial results on July 29, 2026, after market close. A conference call will follow at 5:00 p.m. ET to discuss the results. Participants can access the call via phone or a live audio webcast. A replay will be available for 90 days post-call.
Read more →-TDOC
Jul 3, 2026Teladoc Health Announces Employee Inducement Award under NYSE Rule 303A.08
Teladoc Health has announced the issuance of an inducement award to David Packles, the new Head of Product at BetterHelp. Effective July 1, 2026, Packles received 50,000 restricted stock units, which will vest over three years. This award was approved by the Compensation Committee and aligns with NYSE Rule 303A.08.
Read more →-TDOC
Apr 29, 2026Teladoc Health Reports First Quarter 2026 Results
Teladoc Health reported its financial results for the first quarter of 2026, revealing a 2% decrease in revenue year-over-year, totaling $613.8 million. The company experienced a net loss of $63.8 million, although it reaffirmed its full-year financial outlook. The Integrated Care segment showed growth, while the BetterHelp segment faced a revenue decline. Adjusted EBITDA remained stable, reflecting the company's ongoing efforts to maintain financial performance amidst challenges.
Read more →-TDOC
Apr 15, 2026▲ +5.7%on this news· ran to +16% by day 3
Teladoc Health to Announce First Quarter 2026 Financial Results
Teladoc Health Inc. will announce its first quarter 2026 financial results on April 29, 2026, after market close. A conference call to discuss these results will take place at 5:00 p.m. ET on the same day. Participants can access the call via a dedicated phone line or through a live audio webcast.
Read more →-TDOC
Mar 30, 2026Teladoc Health Appoints Susan Salka, Experienced Healthcare Executive, to Its Board of Directors
Teladoc Health has appointed Susan Salka, former president and CEO of AMN Healthcare, to its board of directors, effective immediately. Salka is expected to bring valuable insights on care delivery transformation as the company pursues scalable health outcomes. She will serve on the board's audit and compensation committees. Her extensive experience in healthcare leadership, including a successful tenure at AMN Healthcare, positions her well to contribute to Teladoc's future growth.
Read more →-TDOC
Feb 25, 2026Teladoc Health Reports Fourth Quarter and Full Year 2025 Results
Teladoc Health reported its financial results for the fourth quarter and full year 2025, revealing flat revenue for Q4 2025 compared to the previous year but a 2% decline for the full year. The company experienced a net loss of $25.1 million in Q4 2025, which was an improvement compared to the $48.4 million loss in the same quarter of 2024. Adjusted EBITDA rose by 12% year-over-year, indicating some operational progress. Despite these improvements, Teladoc faces challenges with a decline in overall revenue and specific segment performance, particularly in BetterHelp.
Read more →-TDOC
Feb 18, 2026Teladoc Health Appoints Michael Smith, Experienced Insurance and Financial Services Executive, to Its Board of Directors
Teladoc Health has appointed Michael Smith to its board of directors, following the retirements of Eric Evans and Thomas McKinley. Smith brings over 30 years of experience in financial management and strategic transformation, previously serving as Vice Chair and CFO of Voya Financial. He will contribute to the audit and nominating committees, expected to enhance Teladoc's strategic direction as it seeks long-term growth. The company will also announce its fourth-quarter 2025 results on February 25, 2026.
Read more →-TDOC
Oct 29, 2025Teladoc Health Reports Third Quarter 2025 Results
Teladoc Health reported its third-quarter results for 2025, revealing a revenue decline of 2% to $626.4 million, alongside a net loss of $49.5 million. While the Integrated Care segment showed modest revenue growth of 2%, the BetterHelp segment experienced an 8% decrease. The adjusted EBITDA also saw a significant drop of 16% in comparison to the previous year. Despite these challenges, the company reiterated its commitment to strategic growth initiatives amid a challenging financial landscape.
Read more →-TDOC
Oct 23, 2025Teladoc Health Announces Chief Financial Officer Transition Provides Preliminary Third Quarter 2025 Consolidated Financial Results, Reaffirms Full-Year 2025 Consolidated Outlook
Teladoc Health announced the resignation of Chief Financial Officer Mala Murthy, who will depart on November 21, 2025. The company has initiated a search for her successor while implementing an interim CFO structure to ensure a smooth transition. Alongside this leadership change, Teladoc reaffirmed its financial outlook for 2025 and provided preliminary results indicating a consolidated revenue of $626.4 million for the third quarter. A conference call is scheduled for October 29, 2025, to further discuss the financial results.
Read more →-TDOC
Jul 29, 2025▼ -8.2%on this news
Teladoc Health Reports Second Quarter 2025 Results
Teladoc Health reported its financial results for Q2 2025, revealing a 2% decline in revenue to $631.9 million compared to Q2 2024. Despite this decline, the company showed a substantially reduced net loss of $32.7 million, reflecting progress in financial management. The Integrated Care segment experienced a revenue increase of 4%, while the BetterHelp segment saw a revenue drop of 9%. Teladoc's CEO, Chuck Divita, expressed optimism regarding the company's ongoing strategic priorities and financial performance.
Read more →-TDOC
Apr 30, 2025Teladoc Health Reports First Quarter 2025 Results PURCHASE, NY
Teladoc Health, Inc. reported mixed financial results for the first quarter of 2025, showing a 3% decline in overall revenue to $629.4 million and a net loss of $93 million. The Integrated Care segment saw a 3% revenue increase, while BetterHelp experienced an 11% decrease in revenue. The acquisition of UpLift Health Technologies is expected to enhance Teladoc's capabilities in virtual mental health services. Despite current financial challenges, the company remains optimistic about future growth opportunities.
Read more →-TDOC
Feb 26, 2025Teladoc Health Reports Full Year and Fourth Quarter 2024 Results PURCHASE, NY
Teladoc Health reported a significant decline in financial performance for the full year and fourth quarter of 2024, with revenues dropping 1% and net losses reaching $1 billion. The company saw strong growth in its Integrated Care segment but faced challenges in the BetterHelp segment, which contributed to a noteworthy goodwill impairment charge. Looking ahead, Teladoc has initiated guidance for 2025 and emphasized a focus on executing plans to unlock growth opportunities while managing costs.
Read more →-TDOC
Oct 30, 2024Teladoc Health Reports Third Quarter 2024 Results PURCHASE, NY
Teladoc Health, a leader in virtual care, reported its financial results for Q3 2024, revealing a revenue decline of 3% year-over-year to $640.5 million. While the company's net loss decreased significantly to $33.3 million compared to the previous year, the BetterHelp segment experienced a notable revenue drop of 10%. Despite this, the Integrated Care segment showed growth and improved adjusted EBITDA margins. The company expects modest revenue growth of low to mid-single digits for the full year of 2024 as it repositions for future performance.
Read more →-TDOC
Jul 31, 2024Teladoc Health Reports Second Quarter 2024 Results PURCHASE, NY
Teladoc Health reported its financial results for Q2 2024, showing a 2% decline in revenue year-over-year, totaling $642.4 million. The company experienced a significant net loss of $837.7 million, largely due to a goodwill impairment charge of $790 million related to its BetterHelp segment. Despite challenges, the Integrated Care segment has grown in revenue by 5% and adjusted EBITDA rose by 24%. The company has withdrawn its financial outlook for the full year of 2024 amid ongoing market uncertainties.
Read more →-TDOC
Jun 10, 2024Teladoc Health Names Chuck Divita as CEO Experienced Healthcare Leader to Head Global Virtual Care Company PURCHASE, NY
Teladoc Health has appointed Chuck Divita as its new Chief Executive Officer, effective immediately. Divita, who previously served as Executive Vice President at GuideWell, brings a wealth of experience in managing significant revenue and strategic growth in the healthcare sector. The decision aims to fortify Teladoc's leadership in whole-person virtual care, with Divita expressing high hopes for advancing the company's strategic priorities and enhancing healthcare outcomes for clients. The announcement also highlights the company's plans to build on its established market position.
Read more →-TDOC
Apr 25, 2024Teladoc Health Reports First Quarter 2024 Results PURCHASE, NY
Teladoc Health, Inc. reported its financial results for the first quarter of 2024, showing a revenue increase of 3% year-over-year to $646.1 million, alongside a net loss of $81.9 million. The company noted a significant rise in adjusted EBITDA by 20%, reaching $63.1 million. However, the BetterHelp segment faced a decline in revenue, decreasing by 4%. Looking forward, Teladoc provided its revenue and adjusted EBITDA outlook for the next quarter, aiming for revenue between $635 and $660 million.
Read more →-TDOC
Apr 5, 2024Teladoc Health Board of Directors Announces Leadership Transition Jason Gorevic to depart the company, effective immediately CFO Mala Murthy appointed acting chief executive Teladoc Health reaffirms guidance PURCHASE, NY
Teladoc Health announced a significant leadership change as Jason Gorevic departs from his CEO position, effective immediately. CFO Mala Murthy has been appointed as the acting CEO while the company searches for a permanent successor. The Board has retained an executive search firm to facilitate this process. Despite the leadership transition, Teladoc Health has reaffirmed its guidance for 2024, highlighting confidence in future growth.
Read more →-TDOC
Feb 20, 2024Teladoc Health Reports Fourth Quarter and Full Year 2023 Results Fourth quarter 2023 revenue increase of 4% and full year 2023 revenue increase of 8% to $2,602.4 million Fourth quarter 2023 net loss of $28.9 million, or
Teladoc Health reported a mixed financial performance for Q4 and full-year 2023, with a revenue increase of 4% in Q4 and 8% for the year, totaling $2,602.4 million. Although the company achieved a significant increase in adjusted EBITDA of 22% for Q4 and 33% for the full year, it also reported a net loss of $28.9 million for Q4 and $220.4 million for the entire year. The company expressed optimism for 2024, providing guidance for revenue growth and adjusted EBITDA, showing cautious but positive expectations.
Read more →-TDOC
Oct 24, 2023Teladoc Health Reports Third Quarter 2023 Results Third quarter 2023 revenue grows 8% year-over-year to $660.2 million Third quarter 2023 operating cash flow of $105.6 million free cash flow of $68.0 million Third quarte
Teladoc Health reported its financial performance for the third quarter of 2023, with revenue increasing 8% year-over-year to $660.2 million. The company achieved an adjusted EBITDA of $88.8 million, a notable 73% rise from the previous year, while free cash flow reached $68 million. Despite the revenue growth and improved operating metrics, Teladoc faced a net loss of $57.1 million. The company is committed to enhancing its virtual care services and has outlined optimistic revenue and EBITDA guidance for the fourth quarter and full year of 2023.
Read more →-TDOC
Sep 20, 2023Teladoc Health Appoints Leading Healthcare and Hospitals Executive Eric Evans to Board of Directors Purchase, NY
Teladoc Health has appointed Eric Evans, a seasoned healthcare executive, to its board of directors, succeeding the retired Senator William Frist, M.D. Evans brings valuable expertise from his tenure at Surgery Partners and Tenet Healthcare, where he achieved substantial growth. His appointment is expected to strengthen Teladoc's strategic direction as it continues to enhance its services and innovate healthcare delivery. Teladoc reports strong financial results, further solidifying its position in the virtual care market.
Read more →-TDOC
Jul 25, 2023Teladoc Health Reports Second Quarter 2023 Results Second quarter 2023 revenue grows 10% year-over-year to $652.4 million Second quarter 2023 operating cash flow of $101.2 million free cash flow of $64.6 million Second q
Teladoc Health reported its financial results for the second quarter of 2023, showing a revenue growth of 10% year-over-year to $652.4 million. The company achieved an adjusted EBITDA of $72.2 million, up 54% from the previous year. However, it also reported a net loss of $65.2 million due to various expenses. The results were bolstered by significant growth in international revenue and strong performance in the Integrated Care and BetterHelp segments.
Read more →-TDOC
Apr 26, 2023Teladoc Health Reports First Quarter 2023 Results First quarter 2023 revenue grows 11% year-over-year to $629.2 million First quarter 2023 net loss of $69.2 million, or $0.42 per share First quarter adjusted EBITDA total
Teladoc Health released its financial results for the first quarter of 2023, reporting an 11% increase in revenue to $629.2 million year-over-year. Despite this growth, the company posted a net loss of $69.2 million, significantly lower than the prior year's loss but still highlighting ongoing challenges. The firm plans to continue investing in innovations while navigating a slight decrease in adjusted EBITDA. Overall, Teladoc remains optimistic about its future performance amid a changing healthcare landscape.
Read more →-TDOC
Feb 22, 2023Teladoc Health Reports Fourth Quarter and Full Year 2022 Results Fourth quarter revenue grows 15% year-over-year to $637.7 million and full year revenue grows 18% year-over-year to $2,406.8 million 2022 full year cash fl
Teladoc Health reported its fourth-quarter and full-year financial results for 2022, showing a revenue increase of 15% year-over-year in Q4, totaling $637.7 million. However, the company faced significant net losses totaling $3.8 billion in Q4 due to non-cash goodwill impairment charges. Despite this, adjusted EBITDA increased by 22% for the quarter. Looking forward, Teladoc expects revenues for 2023 between $2,550 and $2,675 million, with a projected net loss per share between ($1.75) and ($1.25).
Read more →-TDOC
Oct 26, 2022Teladoc Health Reports Third-Quarter 2022 Results Third quarter revenue grows 17% year-over-year to $611.4 million Net loss totaled $73.5 million, or $0.45 per share Adjusted EBITDA totaled $51.2 million Cash flow from o
Teladoc Health Reports Third-Quarter 2022 Results PURCHASE, NY, October 26, 2022- Teladoc Health, Inc. (NYSE: TDOC), the global leader in whole-person virtual care, today reported financial results for the third quarter ended September 30, 2022. "Teladoc Health delivered strong
Read more →-TDOC
Oct 24, 2022Teladoc Health Names Laizer Kornwasser as President, Enterprise Growth & Global Markets PURCHASE, NY
Teladoc Health Names Laizer Kornwasser as President, Enterprise Growth & Global Markets PURCHASE, NY, October 24, 2022 -- Teladoc Health (NYSE: TDOC), the global leader in whole-person virtual care, has named Laizer Kornwasser as president, enterprise growth and global markets
Read more →-TDOC
Jul 27, 2022▲ +7.6%on this news
Teladoc Health Reports Second-Quarter 2022 Results Second quarter revenue grows 18% year-over-year to $592.4 million. Net loss per share of $19.22, primarily driven by non-cash goodwill impairment charge of $3.0 billion,
Teladoc Health Reports Second-Quarter 2022 Results PURCHASE, NY, July 27, 2022- Teladoc Health, Inc. (NYSE: TDOC), the global leader in whole-person virtual care, today reported financial results for the second quarter ended June 30, 2022. "Teladoc Health delivered solid second
Read more →-TDOC
Jul 25, 2022Teladoc Health Names Mike Waters as Chief Operating Officer PURCHASE, NY
Teladoc Health Names Mike Waters as Chief Operating NY, July 25, 2022 -- Teladoc Health (NYSE: TDOC), the global leader in whole-person virtual care, has named Mike Waters as chief operating officer. As COO, Waters will work closely with Jason Gorevic, CEO of Teladoc Health, o
Read more →-TDOC
Apr 27, 2022Teladoc Health Reports First Quarter 2022 Results First quarter revenue grows 25% year-over-year to $565.4 million Net loss per share of $41.58, primarily driven by non-cash goodwill impairment charge of $6.6 billion or
Teladoc Health Reports First Quarter 2022 Results PURCHASE, NY, April 27, 2022- Teladoc Health, Inc. (NYSE: TDOC), the global leader in whole-person virtual care, today reported financial results for the first quarter ended March 31, 2022. "Teladoc Health continues to be the gl
Read more →-TDOC
Feb 22, 2022Teladoc Health Reports Fourth Quarter and Full Year 2021 Results Fourth quarter revenue grows 45% year-over-year to $554.2 million and total visits increase 41% to 4.4 million Full year revenue grows 86% year-over-year t
Teladoc Health Reports Fourth Quarter and Full Year 2021 Results PURCHASE, NY, February 22, 2022- Teladoc Health, Inc. (NYSE: TDOC), the global leader in whole-person virtual care, today reported financial results for the fourth quarter and full year ended December 31, 2021. "T
Read more →-TDOC
Nov 18, 2021▼ -8%on this news· ran to -23% by day 3
This presentation contains, and our officers may make, “forward-looking” statements that are based on our management's beliefs and assumptions and on information currently available to management. These for
Such GAAP measurements include net loss, net loss per share and other performance measures. - In evaluating these financial measures, you should be aware that in the future we may incur expenses similar to those eliminated in this presentation. Our presentation of EBITDA and adju
Read more →-TDOC
Oct 27, 2021Teladoc Health Reports Third-Quarter 2021 Results Third quarter revenue grows 81% year-over-year to $522 million, updating 2021 revenue outlook to $2,015 million to $2,025 million. Total third quarter visits top 3.9 mill
Teladoc Health Reports Third-Quarter 2021 Results PURCHASE, NY, October 27, 2021- Teladoc Health, Inc. (NYSE: TDOC), the global leader in whole-person virtual care, today reported financial results for the quarter ended September 30, 2021. "Our strong performance in the third q
Read more →-TDOC
Jul 27, 2021Teladoc Health Reports Second-Quarter 2021 Results, Raises Full-Year Revenue Guidance Second quarter revenue grows 109% year-over-year to $503 million, driving 2021 revenue outlook increase to $2,000 million to $2,025 mi
Teladoc Health Reports Second-Quarter 2021 Results, Raises Full-Year Revenue Guidance PURCHASE, NY, July 27, 2021- Teladoc Health, Inc. (NYSE: TDOC), the global leader in whole-person virtual care, today reported financial results for the quarter ended June 30, 2021. "Teladoc
Read more →-TDOC
Apr 28, 2021Teladoc Health Reports First-Quarter 2021 Results PURCHASE, NY
Teladoc Health Reports First-Quarter 2021 Results PURCHASE, NY, April 28, 2021- Teladoc Health, Inc. (NYSE: TDOC), the global leader in whole-person virtual care, today reported financial results for the first quarter ended March 31, 2021. "After a transformational year, Telado
Read more →-TDOC
Feb 24, 2021Teladoc Health Reports Fourth-Quarter and Full-Year 2020 Results Q4 revenue grows 145% year-over-year to $383.3 million and total visits increase 139% to 3.0 million Full year revenue grows 98% year-over-year to $1,094.0
Teladoc Health Reports Fourth-Quarter and Full-Year 2020 Results Q4 revenue grows 145% year-over-year to $383.3 million and total visits increase 139% to 3.0 million Full year revenue grows 98% year-over-year to $1,094.0 million and total visits increase 156% to 10.6 million I
Read more →-TDOC
Oct 30, 2020Teladoc Health Completes Merger with Livongo Combination Creates the Global Leader in Whole-Person Virtual Care
Teladoc Health Completes Merger with Combination Creates the Global Leader in Whole-Person Virtual Care October 30, 2020, Purchase, NY - Teladoc Health (NYSE: TDOC), the global leader in whole person virtual care, today announced that it has completed its merger with Livongo.
Read more →-TDOC
Oct 29, 2020Teladoc Health Announces Shareholder Approvals in Merger with Livongo
Health Announces Shareholder Approvals in Merger with Livongo October 29, 2020, Purchase, NY - Teladoc Health (TDOC), the global leader in whole person virtual care, today announced that its shareholders have overwhelmingly showed their support for the merger with Livongo (LVG
Read more →-TDOC
Oct 28, 2020Teladoc Health Reports Third-Quarter 2020 Results Year-over-year Q3 revenue grows 109% to $288.8 million and total visits increase 206% to 2.8 million Year-over-year nine months revenue grows 79% to $710.6 million and to
Teladoc Health Reports Third-Quarter 2020 Results Year-over-year Q3 revenue grows 109% to $288.8 million and total visits increase 206% to 2.8 million Year-over-year nine months revenue grows 79% to $710.6 million and total visits increase 163% to 7.6 million Issues 2020 fourt
Read more →-TDOC
Sep 16, 2020Teladoc Health and Livongo File Definitive Proxy Statement Special Meetings to Be Held on
Teladoc Health and Livongo File Definitive Special Meetings to Be Held on October Unanimously Recommend Stockholders Vote the Merger and Other Proposals Set Forth in the Definitive Proxy Statement Transaction on Track to Close by End of Fourth Quarter of 2020 PURCHASE, NY a
Read more →-TDOC
Sep 3, 2020Transforming Healthcare, Across the Continuum of Care September 2020 Creates the global leader in virtual care across primary, ambulatory, acute, complex and chronic care Positions combined company to lead the market and
Transforming Healthcare, Across the Continuum of Care September 2020 Creates the global leader in virtual care across primary, ambulatory, acute, complex and chronic care Positions combined company to lead the market and set the pace for a rapidly evolving healthcare industry Es
Read more →-TDOC
Aug 5, 2020Teladoc Health and Livongo Merge to Create New Standard in Global Healthcare Delivery, Access and Experience The only consumer centered virtual care platform for full spectrum of health needs to address accelerating cons
Health and Livongo Merge to Create New Standard Healthcare Delivery, Access and Experience Purchase, NY and Mountain View, CA, August 5, 2020 -- Teladoc Health (TDOC), the global leader in virtual care, and Livongo (LVGO), the leading Applied Health Signals company - today an
Read more →-TDOC
Jul 29, 2020Teladoc Health Reports Second-Quarter 2020 Results Year-over-year Q2 revenue grows 85% to $241.0 million and total visits increase 203% to 2.8 million Year-over-year six months revenue grows 63% to $421.8 million and tot
Teladoc Health Reports Second-Quarter 2020 Results Year-over-year Q2 revenue grows 85% to $241.0 million and total visits increase 203% to 2.8 million Year-over-year six months revenue grows 63% to $421.8 million and total visits increase 144% to 4.8 million Issues 2020 third-
Read more →-TDOC
Jul 1, 2020Teladoc Health Completes Acquisition
FOR IMMEDIATE RELESE Teladoc Health Completes Acquisition Creating Single Virtual Care Delivery Leader from Hospital to Home Combined Company Enables Providers to Build Comprehensive Telemedicine Strategies Purchase, NY, July 1, 2020 - Teladoc Health, Inc. (NYSE: TDOC), th
Read more →Competitive Position
How TDOC ranks across every disease it competes inCompetitive Position is a premium feature
See how TDOC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial